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Abstract Quantitative analysis of intracellular analytes
requires an accurate and precise assay not only for the
quantitation of the analytes, but also for the quantitation of
the number of cells in which they were determined. In this
technical note we compare protein and DNA as markers for
the number of peripheral blood mononuclear cells
(PBMCs) isolated from whole blood. The protein content
of samples was highly influenced by red blood cell
contamination and was, therefore, a less suitable marker.
The DNA-based method was unaffected by red blood cell
contamination and was finally validated over a range from
10 × 10





The molecular targets of many drugs are not located in
blood plasma or the exterior of cells, but rather inside
cells. Plasma levels of these compounds can therefore be
regarded only as a surrogate for the actual intracellular
concentrations. Still, determination of plasma levels
appears sufficient for most drugs because an equilibrium
exists between the plasma and the intracellular drug
concentration.
For some drugs and metabolites, however, the plasma
concentrations are not in equilibrium with intracellular
concentrations. This can be due to intracellular accumula-
tion of the drug, or due to intracellular formation of
metabolites.
The active metabolites of nucleoside analogues, which
are used in anticancer, antiviral and immunosuppressive
therapies, are only formed inside cells, and have a half-life
that is much longer than that of their parent nucleoside in
plasma. For these drugs, intracellular metabolite levels are
much more informative than plasma prodrug levels [1].
Most assays for intracellular analytes use peripheral
blood mononuclear cells (PBMCs) as a matrix because of
their role in the immune system and because their
nucleoside metabolism is fully functional, as opposed to
that of red blood cells and platelets.
Intracellular assays require an accurate and precise
determination of the amount of analyte as well as of the
number of cells in which it was determined. Many
publications have described extensive validations of intra-
cellular assays, but these validations generally do not
include the cell counting step [2, 3]. Moreover, separate
validations of cell counting procedures are very sparse [4].
The cell counting step can, however, be a considerable
source of variability [5].
Since the accuracy and precision of the final result is
composed of the accuracy and precision of the cell count
and the final analysis, an accurate and precise cell counting
method is pivotal to obtain correct results. PBMCs have
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protein determinations [2, 6, 7]. More recently, Benech et
al. [4] showed the positive relationship between the number
of PBMCs and DNA content. Using the intercalating agent
SYBR green, they developed and validated a DNA-based
PBMC counting method.
Here, we compare the Bradford protein determination [8]
with a DNA determination using the fluorescent dye
Hoechst 33258 [9] for counting the number of PBMCs in
a sample. Moreover, we describe the validation of a DNA-
based PBMC counting method.
Experimental
Cell isolation and preparation
Red blood cells were obtained by centrifuging whole blood
for 5 min at 1,500g and collecting the precipitate. The cells
were frozen, and the haemoglobin concentration was
determined using a haematology analyser (Cell-Dyn 4000;
Abbott Diagnostics, Abbott Park, IL, USA).
For comparison of cell counting with a haemocytometer,
the protein determination and the DNA determinations,
8 mL whole blood was collected in cell preparation tubes
which contain a Ficoll density gradient (BD Vacutainer
CPT; BD, Franklin Lakes, NJ, USA). After centrifugation
(20 min at 1,500 g), the PBMCs were collected and washed
with 15 mL phosphate-buffered saline (PBS). The cells
were finally resuspended in 70 µL PBS.
For the validation of the DNA-based cell counting
assay, PBMCs were isolated from human leucocyte
buffy coat (Sanquin, Amsterdam, The Netherlands)
originating from 500 mL whole blood, as previously
described [7]. This method also uses a Ficoll density
gradient, but is adapted for the isolation of larger numbers
of PBMCs. The PBMC suspensions obtained were diluted
to the desired concentration with PBS, aliquoted in 10-μL
volumes and stored at -70 °C.
Cell count using a haemocytometer
The number of PBMCs and red blood cells was determined
in each sample using a Cell-Dyn 4000 haematology analyser.
Protein determination
The total protein concentration in samples was determined
using the Bradford protein assay (Bio-Rad protein assay;
Bio-Rad, Hercules, CA, USA). Seven bovine serum
albumin calibration standards were prepared in concen-
trations ranging from 50 to 1,000 μg/mL. Calibration
standards and unknowns were transferred (10 μL) to a 96-
well microplate (BD microtest™, flat bottom; BD, Franklin
Lakes, NJ, USA). All samples were processed in duplicate.
After the addition of 250 μL dye reagent (Coomassie
brilliant blue G-250), the absorption was directly measured
at 590 nm using a microplate reader (EL340; Bio-Tek
Instruments, Winooski, VT, USA).
DNA-based cell count
The DNA-based cell counting was performed using the
fluorescent dye Hoechst 33258 (Bio-Rad DNA quantitation
kit; Bio-Rad, Hercules, CA, USA). Seven PBMC calibra-
tion standards were prepared in concentrations ranging
from 10×10
6 to 300×10
6 PBMCs/mL (determined using a
haemocytometer). Moreover, validation PBMC suspensions
were prepared from a second donor buffy coat at concen-
trations of approximately 10×10
6,7 5 × 1 0
6 and 250×10
6
PBMCs/mL (determined using a haemocytometer). Cali-
bration standards, validation samples and unknowns in PBS
(all 10 µL) were diluted with 750 µL water and sonicated
for 30 min. A 10-μL volume of this suspension was then
transferred to a 96-well opaque microplate (Optiplate-96 F;
PerkinElmer, Waltham, MA, USA) in duplicate. After the
addition of 300 μL dye [2 μg/mL Hoechst 33258 in assay
buffer—2 M NaCl, 100 mM EDTA, 100 mM tris(hydrox-
ymethyl)aminomethane], the microplate was measured five
times within 0.1 s with excitation at 355 nm and emission at
460 nm using a Wallac Victor 1420 (PerkinElmer,
Waltham, MA, USA). The mean of the five measurements
was used for the data processing.
Data processing
Calibration curves were constructed using the Excel 2003
software program (Microsoft, Redmond, WA, USA). For
the protein determination, we used a quadratic fit with 1/x
2
weighting, because absorption is not linear over the
concentration range. For the DNA-based cell count, we
used a linear fit with 1/x
2 weighting. Calibration standards
were excluded if the deviation of the back-calculated
concentration from the nominal concentration was more
than ±15.0% or more than ±20.0% at the lower limit of
quantification (LLOQ). No more than 25% of the calibra-
tion standards were allowed to be rejected from the
calibration curve, which should contain at least one sample
at the LLOQ and the upper limit of quantification. Samples
were only reported if the results from the duplicate analyses
did not deviate more than 15%.
Method comparison
Whole blood was collected from four individuals and
PBMCs were isolated as described in “Cell isolation and
864 R.S. Jansen et al.preparation”. Of the final cell suspension, 20-μL aliquots
were diluted 20-fold in PBS (haemocytometer) and water
(protein determination), or 76-fold in water (DNA determi-
nation). The samples were repeatedly measured using each
method.
Validation of DNA method
Linearity
Deviations of the back-calculated concentrations from the
nominal concentrations should be within ±20 at the LLOQ
and within ±15% at the other levels. No more than one third
of the calibration standards were allowed to be rejected
from the calibration curve.
Inaccuracy and precision
The intra- and interassay inaccuracy and precision were
determined by analysing the validation samples at three
levels in three separate runs (N=5 per run). The inaccu-
racy of the method was assessed by comparing the
determined cell count (DNA-based determination) with
the reference cell count (haemocytometer). The coeffi-
cients of variation were calculated to assess the precision
of the method. Inaccuracies and precisions should be
within ±15% and less than 15%, respectively, except at the
LLOQ, where they should be within ±20% and less than
20%, respectively.
Stability
The stability of the PBMC suspensions was assessed
threefold with samples containing 67.5×10
6 PBMCs/mL.
The stability of non-lysed samples in PBS was assessed
after 7 h at ambient temperatures, and after two freeze
(-70 °C)–thaw cycles. Likewise, the stability was tested in
lysed samples after 2 h at 20–25 °C, and after two freeze
(-70 °C)–thaw cycles. Moreover, the reassay reproducibility
was assessed after storing a microplate for 4.5 h at ambient
temperatures, protected from light. The samples were
considered stable if the concentrations found did not
deviate by more than 15% from the nominal or initial
concentration.
Results and discussion
In studies where we used the Bradford protein assay to
correct for the number of cells isolated from clinical
samples, a small number of samples contained exception-
ally high protein levels. Visual inspection of these samples
revealed a red discoloration. We reasoned that red blood
cell contamination was the source of the high protein levels
observed. Because red blood cells do not contain DNA, a
DNA-based cell counting method was considered.
In preliminary experiments we investigated this possibly
confounding factor more thoroughly by spiking neat
solutions (without PBMCs) and PBMC-containing samples
with red blood cells. Figure 1 clearly shows the impact that
haemoglobin, a marker for red blood cell contamination,
has on the amount of protein in a sample. Even a relatively
low contamination had a significant influence on the total
protein concentration. A red blood cell lysis and wash step
would improve the performance of the protein method, but
requires extra sample handling. The DNA signals were, as
expected, not influenced by the red blood cell contamina-
tion, making the DNA-based cell counting method more
robust towards the inevitable red blood cell contamination.
Therefore, the DNA-based cell counting was developed
further.
Fig. 1 Effect of the haemoglobin concentration on the protein
(dashed line) and the DNA (solid line) concentration in samples with
peripheral blood mononuclear cells (PBMCs) (triangles) and without
PBMCs (circles)
Fig. 2 Protein concentration (closed squares) and DNA-based PBMC
count (open squares) versus cell count obtained using a haemocy-
tometer. Data points are presented as the mean (N=5 for protein
determination and DNA-based cell count, N=3 for haemocytometer
cell count) ± the standard error of the mean
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The fluorescent dye Hoechst 33258 selectively binds to
double-stranded DNA, upon which the fluorescent signal
and absorption wavelength shift [9]. Initially, we prepared
Hoechst 33258 in assay buffer that was diluted ten times.
T h i s ,h o w e v e r ,r e s u l t e di ns l o w l yi n c r e a s i n gf l u o r e s c e n c e
signals, which kept increasing for up to 5 h after addition.
When we used undiluted assay buffer, on the other hand,
the signal rapidly increased, allowing direct analysis.
Others have reported that high salt concentrations disso-
ciate the DNA from proteins in crude cell extracts [9]. Cell
lysis was performed in a relatively large volume of water.
When smaller volumes were used, cell numbers in
samples with a high PBMC concentration were under-
estimated, indicating incomplete dissolution of the DNA.
Finally, we noticed variation in the final measurement of
the microplate. To reduce this variation, each well was
measured five times.
Method comparison
We systematically compared the three methods described
by applying each of them to PBMCs originating from
four different individuals. The results of this comparison
are presented in Fig. 2. With coefficients of variation
lower than 10%, all methods showed good precision.
Moreover, high correlation coefficients were found be-
tween the cell number determined using the haemocy-
tometer and the protein (0.959) and DNA-based results
(0.995). The slightly lower coefficient of correlation for
the protein determination was most likely caused by
variable red blood cell contamination. In agreement with
our preliminary experiments, the samples containing
relatively high numbers of red blood cells showed a
relatively high protein concentration, whereas the DNA-
based method remained unaffected. The cell numbers
determined using the DNA-based method deviated by
9.74–19.1% from the numbers determined using the
haemocytometer.
Table 1 Assay performance of the DNA-based peripheral blood
mononuclear cell (PBMC) counting method. Samples containing
PBMCs at three concentrations were analysed fivefold in three
separate analytical runs
Run Replicate PBMC concentration (10
6/mL)
14.2 67.5 245
1 1 18.2 82.5 243
2 17.0 76.8 232
3 15.5 77.3 233
4 13.3 75.0 232
5 15.4 76.4 232
2 1 11.4 74.5 235
2 14.6 76.3 232
3 12.7 72.3 230
4 12.7 75.1 231
5 8.22 73.6 228
3 1 14.2 69.0 226
2 12.9 70.2 220
3 12.3 65.3 210
4 11.4 70.9 210
5 11.0 70.0 213
Mean 1 15.9 77.6 234
Mean 2 11.9 74.4 231
Mean 3 12.4 69.1 216
Overall mean 13.4 73.7 227
Intra-assay inaccuracy 1 (% dev) 11.8 15.0 -4.33
Intra-assay inaccuracy 2 (% dev) -16.0 10.2 -5.63
Intra-assay inaccuracy 3 (% dev) -13.0 2.34 -11.9
Interassay inaccuracy (% dev) -5.72 9.16 -7.29
Intra-assay precision 1 (% CV) 11.6 3.70 2.06
Intra-assay precision 2 (% CV) 19.8 2.03 1.12
Intra-assay precision 3 (% CV) 10.3 3.21 3.25
Interassay precision (% CV) 18.9 5.70 4.25
dev deviation, CV coefficient of variation
Table 2 Stability data of PBMC samples. Samples containing 67.5×10
6 PBMCs/mL were stored under analytically relevant conditions, after
which the number of PBMCs was determined using the DNA-based counting method (N=3 per condition)






CV (%) Dev (%)
PBS 7 h, ambient temperatures 67.5 70.7 2.62 4.69
(non-lysed) 2 freeze(-70 °C)–thaw cycles 67.5 74.1 6.08 9.78
Water 2 h, ambient temperatures 67.5 73.2 0.993 8.52
(lysed) 2 freeze(-70 °C)–thaw cycles 67.5 64.1 8.99 -5.02
Reassay reproducibility 4.5 h, ambient temperatures,
protected from light
78.9 82.2 1.54 4.18
866 R.S. Jansen et al.Cell counting using a haemocytometer and cell counting
using a microscope remain the reference methods. These
methods, however, require intact cells and must therefore
be performed before freezing the sample. Personnel trained
for PBMC counting should thus be present when each
sample is processed. Moreover, instruments and trained
personnel should be available at each clinical site in the
case of multicentre studies. A standardized assay performed
in a central laboratory reduces the need for instruments and
personnel, and the concomitant analytical variation. Of the
two markers tested, DNA proved to be the most appropriate
for PBMC counting. Therefore, we validated the DNA-
based PBMC counting method.
DNA-based cell count validation
Linearity
The mean back-calculated deviations from the nominal
concentrations of the calibration standards ranged from -6.75
to 3.35% and the precision was better than 10.4% at all
calibration levels. The correlation coefficients were 0.993 or
better.
Inaccuracy and precision
The assay performance is presented in Table 1.T h e
determined mean PBMC concentrations deviated by -5.72,
9.16 and -7.29% from the nominal concentration for the




6 PBMCs/mL, respectively. All precisions were
lower than 15%, except for the lowest validation sample,
where it was lower than 20%. In conclusion, both the
inaccuracy and the precision of the method are satisfactory.
Stability
The stability of the samples under different conditions is
summarized in Table 2. Deviations of less than 15% were
found, showing that the samples were stable under all
conditions tested. Long-term stability tests are ongoing.
Summary
The method described should also be applicable to other
types of cells as long as the amount of DNA per cell is
identical to that of PBMCs. Results obtained from
leukaemic or other malignant cells should, thus, be
interpreted with care because malignant cells often have
an aberrant karyotype and thus contain an aberrant
amount of DNA. Moreover, chemotherapeutic agents
can cause a shift in the cell cycle of dividing cells,
thereby altering the amount of DNA per cell. This is,
however, not a problem for healthy PBMCs, which are
non-dividing.
Conclusions
A DNA-based cell counting method is preferable over a
protein-based method, because inevitable red blood cell
contamination of PBMC samples severely influences the
protein content. The DNA-based method described has
been validated for the accurate and precise determination
of the number of PBMCs present in a sample of isolated
PBMCs. Crude cell suspensions could be used with
minimal sample pretreatment, allowing fast analysis. The
determination is not influenced by red blood cell
contamination.
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